Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy.
Authors
Cagney, Daniel NDunne, Mary
O'Shea, Carmel
Finn, Marie
Noone, Emma
Sheehan, Martina
McDonagh, Lesley
O'Sullivan, Lydia
Thirion, Pierre
Armstrong, John
Issue Date
2017-08-01Keywords
PROSTATE CANCERRADIOTHERAPY
Metadata
Show full item recordCitation
Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy. 2017, 17 (1):60 BMC UrolJournal
BMC urologyDOI
10.1186/s12894-017-0250-2PubMed ID
28764689Abstract
Our aim was to assess the heterogeneity of high-risk (HR) prostate cancer managed with high-dose external beam radiotherapy (EBRT) with androgen deprivation therapy (ADT).Item Type
ArticleLanguage
enISSN
1471-2490ae974a485f413a2113503eed53cd6c53
10.1186/s12894-017-0250-2
Scopus Count
Collections
Related articles
- Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.
- Authors: Tendulkar RD, Reddy CA, Stephans KL, Ciezki JP, Klein EA, Mahadevan A, Kupelian PA
- Issue date: 2012 Mar 15
- Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
- Authors: Naik M, Reddy CA, Stephans KL, Ciezki JP, Garcia J, Grivas P, Stephenson AJ, Klein EA, Tendulkar RD
- Issue date: 2016 Nov 1
- The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
- Authors: Dong Y, Ruth KJ, Churilla TM, Viterbo R, Sobczak ML, Smaldone MC, Chen DY, Uzzo RG, Hallman MH, Horwitz EM
- Issue date: 2017 Feb
- Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
- Authors: Hervás A, Pastor J, González C, Jové J, Gómez A, Casaña M, Villafranca E, Mengual JL, Muñoz V, Henriquez I, Muñoz J, Collado E, Clemente J
- Issue date: 2019 Jul
- The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
- Authors: Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA
- Issue date: 2013 Feb 1